Abstract 377 Figure 1

Conclusions SLN mapping and bilateral SLN detection with ICG in endometrial cancer was not different in laparoscopic and robotic approach, even though patients undergoing robotic approach were older and more obese. Bilateral SLN detection was associated with improved 3-year DFS, but not with 3-year OS, compared to no and unilateral SLN detection.

IGCS20_1405

378 CERVICAL ADENOCARCINOMA. WHAT IS THE REASON FOR REFERRAL?

P Cervantes, R Altamirano*, O Nazzari, A Lagos, M Solari, E Pincheira, J Rojas, E Suarez. Hospital San Borja Arriaran, Chile

10.1136/ijgc-2020-IGCS.327

Introduction The objective of this presentation is to evaluate the reason for referral of patients with a diagnosis of cervical adenocarcinoma treated in the Cervical Pathology Unit of the Hospital San Borja Arriaran.

Material and Method Retrospective analysis of records of patients treated for cervical adenocarcinoma, between the years 2008 to January 2019.

Results Of 5353 positive cytologies studied between January 2008 and January 2019, a total of 105 adenocarcinoma were found, with a median age of 47 years (between 20 to 85 years). Out of these 105 patients: 15% were referred due to clinical suspicion, of which 5 patients (30%) had a visible tumor; and 89 patients (85%) were referred due to altered cytology, corresponding to 2% of the total.

Analyzing the cytology that originated the referral of these 89 patients with abnormal results, 41.5% (37) had a PAP suggestive of adenocarcinoma, 6.7% (6) were suggestive of squamous carcinoma, 28% (25) had a PAP NIE II-III, and 23.5% (21) had an atypical in one of its three varieties [double non-specific atypical: 9.5% (2), glandular atypical: 47.6% (10) and atypical that does not exclude high-grade injury 42.8% (9)].

Conclusions Cervical adenocarcinoma is an emerging entity and it is difficult to diagnose. Screening programs do not necessarily decrease its incidence, on the contrary, they have

become the main source of referral for cervical adenocarcinoma. In our review, it corresponded to 85% of the cases. Despite the difficulty of investigating an adenocarcinoma through PAP, this was the main cause of referral. The referral for clinical suspicion corresponded to 15%.

IGCS20_1406

379 FREQUENCY AND MOLECULAR ASSOCIATIONS OF KRAS MUTATIONS IN GYNECOLOGIC MALIGNANCIES

¹K Kilowski*, ²M Dietrich, ³J Xiu, ¹S Ahmad, ¹M Manyam, ¹C Fitzsimmons, ¹J Kennard, ¹N McKenzie, ¹J Kendrick, ³M Korn, ¹R Holloway. ¹AdventHealth Cancer Institute, USA; ²Florida Cancer Specialists and Research Institute, USA; ³Caris Life Sciences, Medical Affairs, USA

10.1136/ijgc-2020-IGCS.328

Introduction KRAS inhibitors have efficacy with non-small cell lung, pancreatic, and colon cancers. The therapeutic role in gynecologic malignancies remains investigational.

Methods Caris next-generation sequencing profiles of 859 gynecologic cancers from our institution were queried for KRAS- and BRCA-mutations, microsatellite instability (MSI), and tumor mutational burden (TMB). Wilcoxon and Fisher-Exact tests were used for comparison of molecular signatures and $p < 0.05$ was regarded significant.

Results KRAS-mutations were present in 12.7% (33/259) uterine [endometrial cancer (EC)] and 6.7% (27/404) ovarian cancers (OC). KRAS-mutations in Type I vs. Type II EC were 20.7% (19/92) and 9.4% (13/139), respectively, and 3.6% (1/28) sarcoma. KRAS-mt OC by histologies were: papillary serous (9/306, 2.9%), endometrioid (9/23, 39.1%), mucinous (4/5, 80%), MMT (3/38, 7.9%), clear cell (2/17, 11.8%), granulosa (0/10, 0%), and other histology (0/5, 0%) (table 1). KRAS-mutations were limited to exon 2. (for subtypes, see figures 1A and 1B). BRCA1/2-mt and KRAS-mutations were mutually exclusive in both EC and OC. KRAS-mutated EC had a greater association with MSI-H (34.8% KRAS-mt vs 16.4% KRAS-wt, $p=0.0445$) and TMB (median=9 mt/MB vs 8 mt/MB, $p=0.0123$) than KRAS-wt. No difference in TMB and MSI status was seen between KRAS-mt vs KRAS-wt OC.

Abstract 379 Table 1 KRAS mutation rate by histology in uterine (endometrial) and ovarian cancers

Cancer Type	KRAS Mutation	KRAS No Mutation	Total	KRAS Mut %
Endometrial (All)	33	226	259	12.7
Sarcoma	1	27	28	3.6
Type 1	19	73	92	20.7
Type 2	13	126	139	9.4
Ovarian (All)	27	377	404	6.7
Clear Cell	2	15	17	11.8
Endometrioid	9	14	23	39.1
Granulosa	-	10	10	0
Malignant mixed müllerian tumor	3	35	38	7.9
Mucinous	4	1	5	80.0
Serous	9	297	306	2.9
Other	0	5	5	0

A.

B.

Abstract 379 Figure 1 RAS sub-types in uterine (endometrial) and ovarian cancers

Conclusions KRAS mutations in exon 2 are frequent in uterine and ovarian malignancies. Clinical trials evaluating subtype-specific KRAS inhibitors in uterine and ovarian tumors are warranted.

IGCS20_1407

380

DEVELOPING A PROTOCOL FOR PRE-OPERATIVE RADIOLOGICAL STAGING OF LOW-GRADE ENDOMETRIAL CANCER FOR THE THAMES VALLEY CANCER ALLIANCE NETWORK

¹S Smyth*, ²G Tasker. ¹Oxford University Hospitals NHS Foundation Trust, UK; ²Buckinghamshire Healthcare NHS Trust, UK

10.1136/ijgc-2020-IGCS.329

Introduction Currently the Thames Valley Cancer Network does not undertake any preoperative staging for low-grade endometrial cancer. Consequently a number of patients require completion surgery for bilateral pelvic lymph node dissection. Last year 20/178 cases of low-grade endometrial cancer went on to have completion surgery. This review was designed to consider three proposals for preoperative staging, and to determine the impact on the service delivery – both the caseload for the radiology and surgical teams; and the potential for delaying the treatment times. We aim to reduce the number of cases requiring additional surgery/adjuvant therapy.

Methods We undertook a retrospective review over a six-month period of all cases diagnosed with low-grade endometrial cancer, to determine the final histological staging and how many patients had already had an MRI. Our assumption for the modelling was that the MRI staging would accurately

Abstract 380 Table 1

Protocol	Grade/Stage	Patient Number	MRI Current Ad hoc	Extra MRI	Extra cases for Bilateral Pelvic Lymph Node Dissection
1	Stage 1B on ultrasound	22	3	19	0
2	Grade 1 and 2	80	13	67	5
3	Grade 2	17	5	12	5